Fusion Antibodies Completes £1.2 million Financing Round

BELFAST, 25 July 2007 - Fusion Antibodies Ltd., a biotechnology company, focused on the discovery, development and commercialisation of antibody-based therapeutics for cancer, has announced that it has raised £1.2 million (€1.8 million) in a recent financing round. The round included a group of new and existing investors including Crescent Capital, Viridian Growth Fund, QUBIS Ltd., University Challenge Fund and Invest Northern Ireland.

Back to news